HMO Blend Production via Engineered Cells and Glycosyltransferases
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current biotechnological methods for producing human milk oligosaccharide (HMO) blends, particularly those containing LNFP-I and 2′-FL, lack the necessary knowledge and techniques to control the composition and fine-tune the levels of these HMOs, leading to inefficiencies in production and purification processes.
Innovation Solution
A method involving genetically engineered cells expressing specific glycosyltransferases and the colanic acid gene cluster, along with sugar efflux transporters, to produce HMO blends with LNFP-I and 2′-FL as predominant components, allowing for control over the molar ratios of these HMOs through strain engineering and fermentation parameters.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If conventional fermentation methods are used to produce HMO blends, then production can proceed with existing technology, but the composition control and fine-tuning capability of HMO levels is insufficient
Solution Approach 1:
The patent divides the HMO production pathway into distinct enzymatic steps, each controlled by separate glycosyltransferase genes (e.g., fucT for fucosylation, bgaB for galactosylation). This segmentation allows independent optimization and control of each HMO synthesis step, enabling precise composition control without overwhelming system complexity.
Solution Approach 2:
The patent employs parameter changes by modifying fermentation conditions (temperature, pH, substrate concentration) and genetic expression levels to fine-tune HMO composition. For example, adjusting fermentation temperature affects the activity of specific glycosyltransferases, thereby controlling the ratio of different HMOs produced.
2Productivity
If individual HMO purification is performed for each oligosaccharide, then high purity products are obtained, but the production process becomes inefficient and costly
Solution Approach 1:
The patent merges multiple HMO production pathways into a single fermentation system using engineered bacterial strains that simultaneously produce multiple HMOs (e.g., 2'-FL, LNFP-I, LNT) in defined ratios. This combining approach eliminates the need for separate purification lines for each HMO, dramatically improving productivity while maintaining acceptable purity through controlled blend composition.
Solution Approach 2:
The engineered bacterial strain serves multiple functions: it acts as a factory for producing various HMOs, a blending system for achieving desired compositions, and a secretion system for releasing HMOs into the medium. This multi-functionality consolidates what would traditionally require multiple separate processes into a single unified system.
3Adaptability or versatility
If known fucosyltransferases are used for LNFP-I production, then fucosylation activity is achieved, but blends of LNFP-I and 2'-FL cannot be produced
Solution Approach 1:
The patent creates a composite enzymatic system by combining multiple glycosyltransferases (fucT, bgaB, and others) in a single bacterial strain. This composite enzyme system enables the production of complex HMO blends including both LNFP-I and 2'-FL, achieving versatility in blend composition while maintaining sufficient total enzyme activity through synergistic action of multiple enzymes.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables the production of HMO blends with precise LNFP-I and 2′-FL ratios, enhancing yield and sustainability by eliminating the need for individual purification of HMOs and improving the overall conversion efficiency from carbon sources to HMO products.
Implementation Method 1
A method involving genetically engineered cells expressing specific glycosyltransferases and the colanic acid gene cluster
Implementation Method 2
Biotechnological production, such as a fermentation process, of HMOs is a valuable, cost-efficient, and large-scale approach to HMO manufacturing
Data Source
AI summary
The present disclosure relates to a method for the production of a human milk oligosaccharide (HMO) blend with LNFP-I and 2′-FL as the predominant HMO's, the method comprising the steps of providing a genetically engineered cell, which comprises a heterologous β-1,3-N-acetyl-glucosaminyltransferase protein, a heterologous β-1,3-galactosyltransferase protein, a heterologous α-1,2-fucosyltransferase protein, and expresses functionally the colanic acid gene cluster, comprises a native or heterologous regulatory or episomal element for controlling the expression of the proteins and optionally express a heterologous sugar transporter, and culturing the cell in a suitable cell culture medium to express said proteins and to produce an HMO blend.